Kirsten Fischer Selected Research

fludarabine

1/2022	Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.
2/2020	Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG).
1/2020	Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
5/2019	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials.
1/2017	FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.
7/2016	First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
5/2016	Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
5/2016	Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?
1/2016	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
7/2014	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kirsten Fischer Research Topics

Disease

52	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 06/2022 - 10/2009
10	Residual Neoplasm 02/2022 - 03/2017
10	Neoplasms (Cancer) 02/2022 - 05/2011
7	Disease Progression 01/2022 - 01/2015
7	Neutropenia 01/2022 - 03/2014
6	Infections 01/2022 - 03/2014
2	Atrial Fibrillation 01/2022 - 01/2017
1	B-Cell Lymphoma (Lymphoma, B Cell) 02/2022
1	Myocardial Infarction 01/2022
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Exanthema (Rash) 01/2022
1	Hemorrhage 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Leukemia 01/2022
1	Glioblastoma (Glioblastoma Multiforme) 01/2021
1	Multiple Myeloma 01/2021
1	Leukocytosis (Pleocytosis) 01/2021
1	Genomic Instability 01/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021
1	Tumor Lysis Syndrome 12/2020
1	Lymphoid Leukemia 12/2020
1	Sepsis (Septicemia) 01/2020
1	Obesity 01/2020
1	Septic Shock (Toxic Shock Syndrome) 01/2020
1	Trisomy (Trisomies) 01/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020
1	COVID-19 01/2020
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2019
1	Leukoencephalopathies 10/2017
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 10/2017
1	Lymphoma (Lymphomas) 06/2016
1	Mucositis 06/2016
1	Carcinogenesis 10/2015
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2011
1	Pathologic Complete Response 02/2011
1	Body Weight (Weight, Body) 10/2009

Drug/Important Bio-Agent (IBA)

19	Rituximab (Mabthera)FDA Link 02/2022 - 09/2011
16	obinutuzumabIBA 06/2022 - 03/2014
13	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2022 - 08/2013
13	fludarabineIBA 01/2022 - 10/2009
12	venetoclaxIBA 01/2022 - 11/2017
10	ibrutinibIBA 01/2022 - 01/2015
8	Bendamustine Hydrochloride FDA Link 01/2022 - 09/2011
5	Chlorambucil (Leukeran)FDA Link 01/2020 - 10/2009
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 05/2011
3	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 05/2015
3	Lenalidomide (CC 5013)FDA Link 01/2021 - 09/2016
2	tirabrutinibIBA 06/2022 - 04/2022
2	idelalisibIBA 06/2022 - 03/2018
2	Immunoglobulins (Immunoglobulin)IBA 11/2021 - 11/2020
2	ofatumumab FDA Link 01/2021 - 03/2018
2	Thymidine KinaseIBA 01/2020 - 01/2018
1	6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amineIBA 04/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2022
1	Prednisone (Sone)FDA LinkGeneric 02/2022
1	Vincristine (Oncovin)FDA LinkGeneric 02/2022
1	Cytochrome P-450 CYP3AIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2022
1	AnticoagulantsIBA 01/2022
1	hydrogen sulfite (bisulfite)IBA 01/2021
1	acalabrutinibIBA 01/2021
1	Phosphotransferases (Kinase)IBA 12/2020
1	AntibodiesIBA 12/2020
1	pipoxolan (BR 18)IBA 02/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	Genetic Markers (Genetic Marker)IBA 10/2017
1	Alemtuzumab (Campath)FDA Link 03/2017
1	Dihydrotachysterol (AT 10)IBA 03/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2016
1	Cisplatin (Platino)FDA LinkGeneric 06/2016
1	Oxygen (Dioxygen)IBA 06/2016
1	purineIBA 06/2015
1	Tyrosine Kinase InhibitorsIBA 05/2015
1	HLA-DR Antigens (HLA-DR)IBA 05/2011

Therapy/Procedure

16	Therapeutics 02/2022 - 10/2009
5	Drug Therapy (Chemotherapy) 02/2022 - 02/2011
2	Aftercare (After-Treatment) 01/2018 - 01/2016
1	Hematopoietic Stem Cell Transplantation 01/2019
1	Duration of Therapy 03/2018